Write-up: Information has been received from a physician for the pregnancy registry for GARDASIL, concerning a female who on 01-SEP-2010 was vaccinated with the first dose of GARDASIL (lot number not reported) intramuscularly while breastfed her baby was 40 day old (WAES 1009USA00625), it was reported that the mother’s and baby’s health were good (well controlled). On 02-SEP-2010, in the morning, the baby’s condition was still good but in the afternoon the condition suddenly drop. The family immediately took the baby to hospital and it did not help since the baby died shortly after that. The cause of death was not reported, it was also reported as “not recovered from death”. No further information is available.
S.A.N.E. VAX, Inc, a non-profit organization request that the FDA rescind its approval for Gardasil™ as a vaccine to prevent cervical cancer or to prevent genotype-specific human papillomavirus (HPV) infection due to use of an inappropriate primary endpoint and unreliable HPV genotyping methods for efficacy evaluation
EXCERPT: Dear Dr. Hamburg: …This research revealed the fact that in November 2001 the VRBPAC committee allowed the vaccine manufacturer, Merck & Co., Inc., to use: CIN 2/3, AIS, or cervical cancer; i.e. CIN 2/3 or worse by histology- with virology to determine the associated HPV type- as the primary endpoint in the evaluation of a vaccine to prevent cervical cancer. [1] Using this primary endpoint for statistical calculation in the clinical trials invalidates the claimed efficacy of Gardasil™ as a vaccine to prevent cervical cancer. Read entire letter to FDA Director Margaret Hamburg
The rate of chronic health conditions among children in the United States increased from 12.8% in 1994 to 26.6% in 2006, particularly for asthma, obesity, and behavior and learning problems, according to results of a new prospective study published in the February 17 issue of the Journal of the American Medical Association. Read more...
In contrast to the causal conclusion in this study, Independent researchers point to the government’s irrational children’s mass vaccination program as cause of the increased Chronic illness in kids. 1994 to 2004 was the peak height of the use of Thimerosal (mercury) in vaccines. However, the “establishment” continues to look in all the wrong places. We are asked not to eat mercury in fish…but mandated to inject it directly into our children’s bodies. During this peak time most children were vaccinated with as many as 15 shots with mercury. Currently the flu shot has high levels of mercury. Current 2010 recommendations: Vaccinate with seasonal Flu vaccine containing Thimerosal in utero and every year thereafter from 6 months through 19 years old. That is over 20 shots of mercury directly injected into the body See How Mercury Degenerates the brain
Also see: Gardasil Primer on home page where Dr. Bart Classen, a NIH researcher says that his research shows that asthma, obesity and juvenile diabetes is from mass vaccinations.
A shocking report from the National Coalition of Organized Women (NCOW) presented data to the CDC from two different sources demonstrating that the 2009/10 H1N1 vaccines contributed to an estimated 1,588 miscarriages and stillbirths. A corrected estimate may be as high as 3,587 cases. CDC’s
Dr. Marie McCormick hides VAERS miscarriage data Press Release
Raw Data (VAERS) miscarriages & stillbirths, McCormick transcript denying miscarriages click here….
CITIZEN’S COMMISSION ON HUMAN RIGHTS INTERNATIONAL DRUG DATA BASE
The psychiatric drug search engine provides you with complete
information on all drug regulatory warnings and studies on the
dangers of psychiatric drugs in two easy to search sections. FIND OUT ABOUT YOUR DRUG…
Dr. Burzynski has found the cure for cancer. He practices in Texas. The US government has attempted to indict him more than 5 times since 1976. Persecuted at the hands of the FDA with its long arm to the Texas Medical Board, Dr. Burzynski has withstood ALL challenges and continues to save lives today. “If you had a choice between your last meal on earth and this film”…buy this film“-Eileen Dannemann, founder of the Student Vaccine Liberation Army:
Morgellons: Emerging Nanotechnology is Threatening All Living Things
The emerging disease called Morgellons is caused by nano “machines” which are believed to receive specific microwave, EMF and ELF signals and information.There is strong evidence linking Chemtrail aerosol fibers to Morgellons fibers. There are more than 10,000 families who report that they suffer from this disease, Morgellons nano machines are commonly found in all body fluids and orifices, and are believed to routinely achieve total body systemic penetration. Symptoms Go to Morgellons Exposed Website for photos and stories
After 13 years of suffering with Lyme disease (related to Morgellons Disease), a possible cure has been stumbled upon. A cumulative effect of much research has produced the possibility that salt and vitamin C may be all that is needed to beat this elusive illness. Without going into a lot of detail, our theory is that Lyme is not just a bacterial disease, but also an infestation of microfilarial worms. Bacteria, worms, internal mites and the possibility of other creatures have been quite horrifying.Salt cure
YALE AND STANFORD PATENT INFORMATION
Morgellons patents: US 6245531 Polynucleotides Encoding Insect Ecdysone Receptorhttp://www.patentlens.net/imageserver... US 5514578A Polynucleotides Encoding Insect Steroid Hormone Receptor Polypeptides and Cells Transformed With Same http://www.patentlens.net/patentlens/... Inventors: David Hogness, 650-723-6166, tran@cmgm.stanford.edu Michael Koelle, 203-432-5662, Michael.koelle@yale.edu William Seagraves, 203-432-4537, William.seagraves@yale.edu —————————————-—————————————- SPRING HOUSE, Pa.–(BW HealthWire)–May 7, 2002 Agreement grants Invitrogen nonexclusive, worldwide rights to manufacture and sell Ecdysone-Inducible Expression research kits RHeoGene today announced it has egotiated an agreement to grant Invitrogen (Carlsbad, CA) a nonexclusive, worldwide sublicense for sales of Invitrogen’s Ecdysone-Inducible Expression System and related products for research purposes only. RHeoGene holds an exclusive license to Stanford University patents U.S. 5,514,578, 6,245,531 and EP Patent 0517805 that cover sales and use of certain ecdysone-based products. Invitrogen has been manufacturing and selling its Ecdysone- Inducible Expression System under a separate license since 1996. Under its license from RHeoGene, Invitrogen will continue to provide Ecdysone-Inducible Expression System products to academic, government, industrial, and clinical institutions for research purposes. Customers wishing to use ecdysone receptor-based gene expression systems for commercial purposes should contact RHeoGene for a commercial license. “This licensing agreement is the first external validation of the importance of RHeoGene’s exclusive license to the intellectual property encompassed by these Stanford patents after broader claims to U.S. 5,514,578 were granted,” said Tom Tillett, RHeoGene Executive Vice President for Operations. The Stanford patents are directed to genes that encode insect-based ecdysone receptors from a broad range of insect species and methods for regulating gene expression in host cells. The patent coverage includes ecdysone receptor (EcR) genes originating from Drosophila, the basis of Invitrogen’s Ecdysone-Inducible Expression System. The patents are based on the pioneering research of Dr. David Hogness, Emeritus Munzer Professor of Developmental Biology and Biochemistry at Stanford University. RHeoGene’s exclusive license to these patents encompasses all uses outside of plants, including cell-based assays, genomics, proteomics, gene therapy, cell culture/fermentation, transgenic animals, and biosensors. RHeoGene focuses on delivering customized inducible gene expression technology systems to advance proteomics, drug discovery, biotherapeutics production, and human gene therapy. RHeoGene’s operations are located in Spring House, Pa., and Charlottesville, Va. For more information, visit www.rheogene.com.
VAERS REPORT: 129 new adverse reaction reports since the beginning of October including 2 death reports. Here’s one:
